BioVaxys Technology Corp, a Canadian biotechnology company, has been making strides in the development of vaccines and immunotherapy products. Headquartered in Vancouver, British Columbia, the company was incorporated in 2001 and has since been a significant player in life sciences research and development. BioVaxys is dedicated to addressing global health challenges, with a particular focus on infectious diseases and cancer.
The company’s mission is to revolutionize the treatment and prevention of infectious diseases and to pioneer new immunotherapy approaches for cancer. One of its flagship products is VaxMite, a novel vaccine currently in development aimed at protecting against Plasmodium falciparum, the most lethal form of malaria. This innovative vaccine represents a critical step forward in the fight against malaria, a disease that continues to have a devastating impact on global health.
In addition to VaxMite, BioVaxys is exploring the potential applications of its technology platform across various medical and healthcare fields. The company’s commitment to innovation is evident in its ongoing research and development efforts, which aim to bring new solutions to the forefront of global health challenges.
Financially, BioVaxys Technology Corp is listed on the Canadian National Stock Exchange, with its shares priced at CAD 0.07 as of May 21, 2026. The company’s market capitalization stands at CAD 2,845,792. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of CAD 0.28 on November 23, 2025, and a low of CAD 0.03 on April 12, 2026. The price-to-earnings ratio is currently -0.532, reflecting the company’s ongoing investment in research and development, which has yet to yield significant earnings.
BioVaxys Technology Corp continues to focus on its core mission of developing innovative solutions to some of the world’s most pressing health issues. With its strong emphasis on research and development, the company is poised to make significant contributions to the fields of infectious disease prevention and cancer immunotherapy.
